COVID-19
Arcturus Therapeutics announced positive Phase III trial results for its mRNA vaccine candidate, ARCT-154, intended to prevent COVID-19 caused by the SARS-CoV-2 virus.
More than two years into the COVID-19 pandemic, some experts, business leaders and government agencies are starting to prep for the next potential pandemic.
Following first-quarter results, Johnson & Johnson is projecting almost $1 billion less in revenue for the year than the initial guidance it gave in January.
Two investigational drugs have been taking the spotlight recently from Revive and Ascletis as they share news regarding their potential treatment against COVID-19.
Pharma giant Moderna has shared data on the development of a new bivalent COVID-19 booster vaccine that performs better than its first booster that is currently on the market.
To cope, life sciences companies are undertaking a supply chain risk assessment, conducting make-or-buy assessments, investing in supply chain technology and identifying backup suppliers.
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
The Chinese government has halted the recommendation of Lianhua Qingwen used as a traditional Chinese treatment for mild cases of COVID-19.
There are very few ongoing clinical trials on treatments for Long COVID and there has been what appears to be a successful treatment using Pfizer’s Paxlovid. Read on for more details.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
PRESS RELEASES